Zai Lab Ltd.

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirati Therapeutics

SAN DIEGO and SHANGHAI and SAN FRANCISCO, June 1, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the companies have entered into a collaboration and license agreement for adagrasib, a small-molecule KRASG12C inhibitor, in Greater China (mainland China, Hong Kong, Macau and Taiwan). "We believe Zai Lab is an ideal partner to enable us to expand and accelerate Mirati's global adagrasib development," said Charles M.

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China

SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced dosing of the first patient in China in the registrational Phase 2 portion of TRIDENT-1 study of repotrectinib being conducted by its partner Turning Point Therapeutics, Inc. and Zai Lab in patients with ROS1+ advanced non-small cell lung cancer (NSCLC) and NTRK+ advanced solid tumors. Zai Lab has an exclusive license agreement with Turning Point for the development and commercialization of repotrectinib in Greater China (mainland China, Hong Kong, Macau, and Taiwan).

Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib

SHANGHAI and SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in June:

Zai Lab Announces Upcoming Presentations in June Investor Conferences

SHANGHAI and SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced treatment of the first patient in Greater China in the METIS trial, a Phase 3 pivotal trial being conducted by Zai's partner NovoCure Limited (NASDAQ: NVCR) to study radiosurgery plus Tumor Treating Fields (TTFields) compared to radiosurgery alone for the treatment of brain metastases from non-small cell lung cancer (NSCLC).

Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

Zai Lab Limited (ZLAB) CEO Samantha Du on Q1 2021 Results - Earnings Call Transcript

Company to Host Conference Call and Webcast Today at 8:00 a.m. EDT Company to Host Conference Call and Webcast Today at 8:00 a.m. EDT

Zai Lab Announces First Quarter 2021 Financial Results

Company to Host Conference Call and Webcast on May 10, 2021 at 8:00 a.m. ET Company to Host Conference Call and Webcast on May 10, 2021 at 8:00 a.m. ET

Zai Lab to Announce First Quarter 2021 Financial Results on May 10, 2021

Week In Review: Zai Lab Raises $750 Million In Private Placement For In-Licensed/Novel Drugs

SHANGHAI and SAN FRANCISCO, April 23, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB, HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 4,776,000 American depositary shares (“ADSs”), each representing one ordinary share of the Company, at a price of US$150.00 per ADS (the “ADS Offering”). Zai Lab had also granted the underwriters a 30-day option to purchase up to an additional 716,400 ADSs at the public offering price, less underwriting discounts and commissions. The underwriters fully exercised their option to purchase these additional ADSs. The ADS Offering closed on April 23, 2021.

Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option

The stock price of Zai Lab Ltd (NASDAQ: ZLAB) increased by over 5% pre-market. This is why it happened.

ZLAB Stock: Over 5% Increase Pre-Market Explanation

SHANGHAI and SAN FRANCISCO, April 20, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB, HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 4,776,000 American depositary shares (“ADSs”), each representing one ordinary share of the Company, at a price of US$150.00 per ADS, and 224,000 ordinary shares, at a price of HK$1164.20 per ordinary share, which will be settled in Hong Kong dollars, based upon each ADS representing one ordinary share and an exchange rate of HK$7.7613 to US$1.00, the spot rate of exchange at the time of pricing.

Zai Lab Announces Pricing of Public Offering of American Depositary Shares and Ordinary Shares

The stock price of Zai Lab Limited (NASDAQ:ZLAB) fell by over 5% pre-market. This is why it happened.

ZLAB Stock: Over 5% Decrease Pre-Market Explanation

Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial

Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer

China NMPA approval follows 2020 U.S. FDA approval for the treatment of patients with fourth-line GIST

China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)

Denali Therapeutics

Fate Therapeutics

Moderna

Novavax

Seagen

If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines appeared first on InvestorPlace.

7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines

Zai Lab Limited (ZLAB) CEO Samantha Du on Q4 2020 Results - Earnings Call Transcript

Company to Host Conference Call and Webcast on March 1, 2021 at 8:00 a.m. ET Company to Host Conference Call and Webcast on March 1, 2021 at 8:00 a.m. ET

Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021

SHANGHAI and SAN FRANCISCO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that senior management from Zai Lab will be presenting in the following upcoming virtual investor conferences in February. Details are as follows:

Zai Lab Announces Upcoming Presentations in February Investor Conferences

Turning Point Therapeutics

Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point's MET/SRC/CSF1R Inhibitor, in Greater China

Turning Point and Zai Lab Broaden Collaboration

argenx

EyePoint Pharmaceuticals

Gilead Sciences

Gracell Biotechnologies

Inovio Pharmaceuticals

Eli Lilly

Paratek Pharma

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments.

Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs

argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China

AdaptHealth Corp

iRhythm Technologies

Retractable Technologies

Sanara MedTech Inc.

These companies made millions by developing equipment for life-saving care, and enriched shareholders too.

These Were the 5 Best Medical Device Stocks of 2020

SHANGHAI and SAN FRANCISCO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 11:40 a.m. EST.

Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference

SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA® has been included in the updated National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA). ZEJULA (niraparib) is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor with national Category 1 designation. It has been included in the NRDL as maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China's National Reimbursement Drug List

- Zai Lab to lead development and commercialization of CLN-081 in Greater China

Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China

News for Zai Lab Ltd. Stock (ZLAB)